News Conference News AHA 2025 Olezarsen Cuts Triglycerides, Pancreatitis Risk in Severe Hypertriglyceridemia Michael O'Riordan November 14, 2025
News Conference News AHA 2025 Stopping DOACs After Successful AF Ablation Feasible in Low-risk Patients: OCEAN Michael O'Riordan November 08, 2025
News Conference News AHA 2024 Rivaroxaban Doesn’t Cut Cognitive Decline, Stroke, or TIA in Younger AF Patients Shelley Wood November 16, 2024
News Conference News ACC 2024 Coronary Sinus Reducer Eases Symptoms in Refractory Angina: ORBITA-COSMIC Michael O'Riordan April 08, 2024
News Conference News ACC 2023 Viability Testing Fails to Find HF Patients Who’d Benefit From PCI in REVIVED-BCIS2 Michael O'Riordan March 09, 2023
News Conference News ESC 2022 Factor XIa Inhibitors Show Potential for Safer Anticoagulation After MI, Stroke Todd Neale August 28, 2022
News Conference News ACC 2022 ADAPT-TAVR: Edoxaban No Better Than DAPT After TAVI Todd Neale April 05, 2022
News Conference News HRS 2021 STROKE-VT: DOACs Cut Cerebrovascular Events After LV Arrhythmia Ablation Todd Neale July 29, 2021
News Conference News ISC 2020 Optimal Time to Start Anticoagulation After Stroke Remains Unclear Todd Neale February 27, 2020
News Conference News AHA 2019 More Ischemia on Stress Echo Equals Greater Angina Benefit With PCI: ORBITA Michael O'Riordan November 14, 2019
News Conference News AHA 2018 EMPA-HEART Offers Mechanistic Clues for Empagliflozin’s Cardiac Benefits Michael O'Riordan November 16, 2018
News Conference News ACC 2017 High-Dose Atorvastatin Does Not Impact Cognition, but Small Changes Observed on Brain MRI Michael O'Riordan March 21, 2017
News Conference News ACC 2017 ACC 2017: CVD Outcomes for Evolocumab, Intermediate-Risk TAVR, Coronary Physiology Tests, and More Shelley Wood March 10, 2017